atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
New York-based Claryx has emerged from stealth with $3.5 million in pre-seed funding.
Outlander VC led the round, with participation from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford and Precursor Ventures.
The funding will help Claryx continue to "build…
Researchers have shown that measurements taken from a person's fingertip could help identify physical patterns associated with stress, anxiety and depression.
The international study, involving experts from Aston University, used a wearable device that shines light into the skin to…
Attendees
Sponsors and Exhibitors
Contact us